ImmunityBio (IBRX) Operating Leases (2019 - 2026)

ImmunityBio (IBRX) has 8 years of Operating Leases data on file, last reported at $33.1 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $33.1 million, down 18.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.1 million (down 18.27% YoY), and the FY2025 annual result was $33.4 million, down 3.95% from the prior year.
• Operating Leases declined to $33.1 million in Q1 2026 per IBRX's latest filing, from $33.4 million in the prior quarter.
• Over five years, Operating Leases peaked at $52.1 million in Q2 2022 and troughed at $33.1 million in Q1 2026.
• A 5-year average of $42.4 million and a median of $42.7 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2026: Operating Leases surged 118.99% in 2022, then dropped 18.27% in 2026.
• A 5-year view of Operating Leases shows it stood at $48.0 million in 2022, then retreated by 16.7% to $39.9 million in 2023, then retreated by 12.82% to $34.8 million in 2024, then decreased by 3.95% to $33.4 million in 2025, then fell by 0.9% to $33.1 million in 2026.
• Business Quant data shows IBRX's Operating Leases at $33.1 million in Q1 2026, $33.4 million in Q4 2025, and $41.4 million in Q3 2025.